Urovant Sciences’ US$681 Million Merger With Sumitovant Biopharma

Urovant Sciences' US$681 Million Merger With Sumitovant Biopharma

O’Melveny & Myers LLP advised Urovant Sciences on the deal.

Urovant Sciences announced its US$681 million definitive merger agreement with Sumitovant Biopharma.

According to the terms of the deal, Sumitovant will acquire the outstanding shares of Urovant common stock not already owned by Sumitovant for US$16.25 per share in cash. Sumitovant currently owns approximately 72 percent of the outstanding shares of Urovant common stock.

Urovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Sumitovant is a global biopharmaceutical company with offices in New York City and London.

The cross-practice O’Melveny team was led by Corporate partner Mark Peterson (Picture), counsel Noah Kornblith and Cem Surmeli (M&A), and associate Mollie Yeh. Also advising on the deal were partners Andrew Dolak (intellectual property), Chris Del Rosso (executive compensation), Bob Fisher (tax), Shelly Heyduk (corporate governance), and Jennifer Taylor (corporate finance), as well as counsel Aaron Cha and associate John Chong.

Involved fees earner: Chris Del Rosso – O’Melveny & Myers LLP; Andrew Dolak – O’Melveny & Myers LLP; Robert Fisher – O’Melveny & Myers LLP; Shelly Heyduk – O’Melveny & Myers LLP; Noah Kornblith – O’Melveny & Myers LLP; Mark Peterson – O’Melveny & Myers LLP; Jennifer Taylor – O’Melveny & Myers LLP;

Law Firms: O’Melveny & Myers LLP;

Clients: Urovant Sciences;


Author: Ambrogio Visconti